Trial Profile
Single-center, Open-label Study With 14C-radiolabeled ACT-132577 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 09 May 2017 Status changed from recruiting to completed.
- 06 Apr 2017 New trial record